{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:22:29Z","timestamp":1789014149216,"version":"build-2803163510"},"reference-count":79,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jtct.2023.04.003","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T11:58:44Z","timestamp":1680868724000},"page":"440-448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed\/Refractory Diffuse Large B Cell Lymphoma"],"prefix":"10.1016","volume":"29","author":[{"given":"Marc S.","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley D.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Cobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C.","family":"Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9060-8911","authenticated-orcid":false,"given":"Javier","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.04.003_bib0001","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/asheducation.V2009.1.523.0010523","article-title":"The 2008 WHO classification of lymphomas: implications for clinical practice and translational research","volume":"2009","author":"Jaffe","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2023.04.003_bib0002","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","volume":"2011","author":"Friedberg","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2023.04.003_bib0003","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.04.003_bib0004","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ajh.26151","article-title":"2021 Update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management","volume":"96","author":"Susanibar-Adaniya","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2023.04.003_bib0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.jtct.2023.04.003_bib0006","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.04.003_bib0007","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.04.003_bib0008","series-title":"Kymriah [prescribing information]","year":"2017"},{"key":"10.1016\/j.jtct.2023.04.003_bib0009","series-title":"Breyanzi [prescribing information]","year":"2021"},{"key":"10.1016\/j.jtct.2023.04.003_bib0010","series-title":"Yescarta [prescribing information]","year":"2022"},{"key":"10.1016\/j.jtct.2023.04.003_bib0011","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.04.003_bib0012","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.04.003_bib0013","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.04.003_bib0014","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jtct.2022.07.011","article-title":"Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B cell lymphomas","volume":"28","author":"Riedell","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.04.003_bib0015","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2023.04.003_bib0016","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jtct.2023.04.003_bib0017","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.7571","article-title":"Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity","volume":"40","author":"Locke","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.04.003_bib0018","article-title":"Enrollment of Black Americans in pivotal clinical trials supporting Food and Drug Administration (FDA) chimeric antigen receptor (CAR)-T cell therapy approval in hematological malignancies","volume":"138","author":"Al Hadidi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.04.003_bib0019","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1182\/bloodadvances.2022007676","article-title":"The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes","volume":"6","author":"Faruqi","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.04.003_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.28877","article-title":"Geographic and racial disparities in access to chimeric antigen receptor-T cells and bispecific antibodies trials for multiple myeloma","volume":"5","author":"Alqazaqi","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtct.2023.04.003_bib0021","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.04.003_bib0022","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jtct.2022.09.020","article-title":"The ASTCT-NMDP ACCESS Initiative: a collaboration to address and sustain equal outcomes for all across the hematopoietic cell transplantation and cellular therapy ecosystem","volume":"28","author":"Auletta","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.04.003_bib0023","first-page":"328","article-title":"Referral patterns and clinical outcomes for transplant-eligible lymphoma and myeloma patients evaluated at an urban county hospital","volume":"6","author":"Yun","year":"2016","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jtct.2023.04.003_bib0024","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/bmt.2012.95","article-title":"Practice variation in physician referral for allogeneic hematopoietic cell transplantation","volume":"48","author":"Pidala","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.003_bib0025","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.6004\/jnccn.2019.7327","article-title":"Addressing knowledge gaps in acute myeloid leukemia to improve referral for hematopoietic cell transplantation consultation","volume":"17","author":"Meyer","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.jtct.2023.04.003_bib0026","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jtct.2022.07.015","article-title":"Chimeric antigen receptor T cell therapy versus hematopoietic stem cell transplantation: an evolving perspective","volume":"28","author":"Goldsmith","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.04.003_bib0027","first-page":"1","article-title":"Expanding access to chimeric antigen receptor T-cell therapies: challenges and opportunities","volume":"40","author":"Kansagra","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jtct.2023.04.003_bib0028","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/bmt.2015.246","article-title":"Geographic access to hematopoietic cell transplantation services in the United States","volume":"51","author":"Delamater","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.003_bib0029","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMp1807382","article-title":"National coverage analysis of CAR-T therapies - policy, evidence, and payment","volume":"379","author":"Bach","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.04.003_bib0030","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1001\/jama.2017.15218","article-title":"FDA approval of tisagenlecleucel: promise and complexities of a $475,000 cancer drug","volume":"318","author":"Bach","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2023.04.003_bib0031","first-page":"4253","article-title":"Caregiver availability and patient access to hematopoietic cell transplantation: social worker perspectives inform practice","volume":"27","author":"Preussler","year":"2019","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jtct.2023.04.003_bib0032","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.04.003_bib0033","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/13696998.2018.1529674","article-title":"Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States","volume":"21","author":"Roth","year":"2018","journal-title":"J Med Econ"},{"key":"10.1016\/j.jtct.2023.04.003_bib0034","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.0035","article-title":"Long-term survival and cost-effectiveness associated with axicabtagene ciloleucel vs chemotherapy for treatment of B-cell lymphoma","volume":"2","author":"Whittington","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtct.2023.04.003_bib0035","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.clinthera.2021.06.011","article-title":"Cost-effectiveness analysis of tisagenlecleucel for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma in the United States","volume":"43","author":"Qi","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.jtct.2023.04.003_bib0036","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood.2022016747","article-title":"Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma","volume":"140","author":"Kambhampati","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.04.003_bib0037","doi-asserted-by":"crossref","first-page":"750.e1","DOI":"10.1016\/j.jtct.2022.08.010","article-title":"The cost-effectiveness of axicabtagene ciloleucel as second-line therapy in patients with large B-cell lymphoma in the United States: an economic evaluation of the ZUMA-7 trial","volume":"28","author":"Perales","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.04.003_bib0038","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jtct.2022.06.019","article-title":"Role of CD19 chimeric antigen receptor T cells in second-line large B cell lymphoma: lessons from phase 3 trials. An expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"28","author":"Perales","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.04.003_bib0039","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CCM.0000000000005149","article-title":"Critically ill patients treated for chimeric antigen receptor-related toxicity: a multicenter study","volume":"50","author":"Gutierrez","year":"2022","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jtct.2023.04.003_bib0040","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.003_bib0041","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/TCRM.S150524","article-title":"Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy","volume":"15","author":"Riegler","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jtct.2023.04.003_bib0042","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.04.003_bib0043","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.04.003_bib0044","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood-2021-149103","article-title":"Pilot implementation of remote patient monitoring program for outpatient management of CAR-T cell therapy","volume":"138","author":"Paludo","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.04.003_bib0045","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/ajt.16315","article-title":"Findings and recommendations from the organ transplant caregiver initiative: moving clinical care and research forward","volume":"21","author":"Jesse","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jtct.2023.04.003_bib0046","unstructured":"Memorial Sloan Kettering Cancer Center. CAR T cell therapy: a guide for adult patients & caregivers. Available at: https:\/\/www.mskcc.org\/cancer-care\/patient-education\/car-cell-therapy-guide-adult-patients-caregivers. Accessed February 7, 2022."},{"key":"10.1016\/j.jtct.2023.04.003_bib0047","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/bmt.2016.164","article-title":"A scoping review of caregiver burden during allogeneic HSCT: lessons learned and future directions","volume":"51","author":"Applebaum","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 3","key":"10.1016\/j.jtct.2023.04.003_bib0048","first-page":"29","article-title":"Educating multidisciplinary care teams, patients, and caregivers on CAR T-cell therapy","volume":"10","author":"Beaupierre","year":"2019","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.jtct.2023.04.003_bib0049","unstructured":"Cory Booker. Booker reintroduces legislation protecting family caregivers from discrimination. Available at: https:\/\/www.booker.senate.gov\/news\/press\/booker-reintroduces-legislation-protecting-family-caregivers-from-discrimination. Accessed February 3, 2023."},{"key":"10.1016\/j.jtct.2023.04.003_bib0050","unstructured":"RAISE Act Family Caregiving Advisory Council and The Advisory Council to Support Grandparents Raising Grandchildren. 2022 National strategy to support family caregivers. Available at: https:\/\/acl.gov\/sites\/default\/files\/RAISE_SGRG\/NatlStrategyToSupportFamilyCaregivers.pdf. Accessed February 3, 2023"},{"key":"10.1016\/j.jtct.2023.04.003_bib0051","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtct.2023.04.003_bib0052","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1097\/HS9.0000000000000524","article-title":"Health economic aspects of chimeric antigen receptor T-cell therapies for hematological cancers: present and future","volume":"5","author":"Heine","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.jtct.2023.04.003_bib0053","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211053120","article-title":"Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma","volume":"12","author":"Rampotas","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtct.2023.04.003_bib0054","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2217\/imt-2020-0118","article-title":"Perceptions of community hematologists\/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma","volume":"12","author":"Gajra","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jtct.2023.04.003_bib0055","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1080\/10428194.2020.1786563","article-title":"Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas","volume":"61","author":"Johnson","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"15_suppl","key":"10.1016\/j.jtct.2023.04.003_bib0056","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1200\/JCO.2020.38.15_suppl.8039","article-title":"Real-world outcomes of elderly patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy","volume":"38","author":"Fitzgerald","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.04.003_bib0057","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2018-04-839217","article-title":"Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed\/refractory diffuse large B-cell lymphoma","volume":"132","author":"Chow","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.04.003_bib0058","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jval.2022.02.007","article-title":"Value of reducing wait times for chimeric antigen receptor T-cell treatment: evidence from randomized controlled trial data on tisagenlecleucel for diffuse large B-cell lymphoma","volume":"25","author":"Chen","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.jtct.2023.04.003_bib0059","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.clml.2022.05.004","article-title":"Severity of cytokine release syndrome influences outcome after axicabtagene ciloleucel for large B cell lymphoma: results from the US lymphoma CAR-T Consortium","volume":"22","author":"Jacobs","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2023.04.003_bib0060","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2023.04.003_bib0061","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2023.04.003_bib0062","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","article-title":"Optimizing CAR-T cell manufacturing processes during pivotal clinical trials","volume":"16","author":"Tyagarajan","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtct.2023.04.003_bib0063","unstructured":"Kite Pharma Inc. How Yescarta works. Available at: https:\/\/www.yescartahcp.com\/large-b-cell-lymphoma\/how-yescarta-works. Accessed May 24, 2022."},{"key":"10.1016\/j.jtct.2023.04.003_bib0064","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2023.04.003_bib0065","unstructured":"Novartis Pharmaceuticals Corporation. KYMRIAH Treatment process. Available at: https:\/\/www.hcp.novartis.com\/products\/kymriah\/diffuse-large-b-cell-lymphoma-adults\/treatment-process\/. Accessed February 8, 2022."},{"key":"10.1016\/j.jtct.2023.04.003_bib0066","unstructured":"Celgene Inc. Breyzani [product monograph]. Available at: https:\/\/www.bms.com\/assets\/bms\/ca\/documents\/productmonograph\/BREYANZI_EN_PM.pdf. Accessed July 1, 2022."},{"key":"10.1016\/j.jtct.2023.04.003_bib0067","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1182\/bloodadvances.2022007776","article-title":"Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy","volume":"6","author":"Rejeski","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.04.003_bib0068","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jtct.2022.02.017","article-title":"Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma","volume":"28","author":"Kedmi","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.04.003_bib0069","doi-asserted-by":"crossref","first-page":"7200","DOI":"10.1038\/s41467-021-27312-6","article-title":"Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients","volume":"12","author":"Maschan","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2023.04.003_bib0070","doi-asserted-by":"crossref","first-page":"e03779","DOI":"10.1016\/j.heliyon.2020.e03779","article-title":"CAR T cell therapy: newer approaches to counter resistance and cost","volume":"6","author":"Yadav","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.jtct.2023.04.003_bib0071","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/jcm10020188","article-title":"Integrating academic and community cancer care and research through multidisciplinary oncology pathways for value-based care: a review and the City of Hope experience","volume":"10","author":"Bosserman","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtct.2023.04.003_bib0072","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jtct.2023.04.003_bib0073","first-page":"2118","article-title":"Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms","volume":"53","author":"Kurzrock","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtct.2023.04.003_bib0074","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26914","article-title":"Hypogammaglobulinemia due to CAR T-cell therapy","volume":"65","author":"Doan","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2023.04.003_bib0075","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.04.003_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T\u2013and a side order of IgG, to go? Immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtct.2023.04.003_bib0077","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2217\/imt.14.67","article-title":"An update on the use of immunoglobulin for the treatment of immunodeficiency disorders","volume":"6","author":"Albin","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jtct.2023.04.003_bib0078","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jtct.2023.04.003_bib0079","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood.2019004162","article-title":"Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"135","author":"Neelapu","year":"2020","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723012344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723012344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:10:39Z","timestamp":1763003439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723012344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":79,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2666636723012344"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.04.003","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed\/Refractory Diffuse Large B Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}